AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20008235 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ASCT strategies (salvage radiotherapy or non-ASCT chemotherapy)
Number of subjects: 0
Study 17464688 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (CCBT)
Number of subjects: 0
Study 17464688 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15675207 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 1% lignocaine pre‐treatment followed by propofol and 2 ml saline
Number of subjects: 100
Study 15675207 — intervention group
Group type: COMPARATOR
Intervention: 4 ml saline followed by propofol and 2 ml 2% lignocaine
Number of subjects: 100
Study 11704028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin and mineral supplements
Number of subjects: 1230
Study 11704028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study 9042042 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula with Lactobacillus GG (5 x 10(8) colony-forming units/gm formula)
Number of subjects: 27
Study 9042042 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula with Lactobacillus GG
Number of subjects: 27
Study 9042042 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula without Lactobacillus GG
Number of subjects: 27
Study 9042042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without Lactobacillus GG)
Number of subjects: 27
Study 7699575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin
Number of subjects: 10
Study 7699575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2853459 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 237
Study 2853459 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 units every 8 hours)
Number of subjects: 237
Study 30516625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) 50 mg/kg loading dose and 10 mg/kg/h infusion
Number of subjects: 111
Study 30516625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 111
Study 30516625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 27671885 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Number of subjects: 43
Study 27671885 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 43
Study 25609939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (AChEIs)
Number of subjects: 105
Study 25609939 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent medications considered strong or moderate inhibitors of CYP2D6
Number of subjects: 105
Study 25609939 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent medications considered strong or moderate inhibitors of CYP3A4/5
Number of subjects: 105
Study 25609939 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 activity score
Number of subjects: 105
Study 23025837 — intervention group
Group type: EXPERIMENTAL
Intervention: brotizolam
Number of subjects: 253
Study 23025837 — intervention group
Group type: COMPARATOR
Intervention: estazolam
Number of subjects: 253
Study 20873909 — intervention group
Group type: EXPERIMENTAL
Intervention: CCAL (computer-assisted cognitive behavioral therapy)
Number of subjects: 49
Study 20873909 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT (individual cognitive behavioral therapy)
Number of subjects: 49
Study 20873909 — intervention group
Group type: COMPARATOR
Intervention: CESA (computer-assisted education, support, and attention)
Number of subjects: 49
Study 20873909 — intervention group
Group type: EXPERIMENTAL
Intervention: CCAL and ICBT
Number of subjects: 49
Study 19102419 — intervention group
Group type: COMPARATOR
Intervention: Sitting position (control group)
Number of subjects: 10
Study 19102419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying position
Number of subjects: 10
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool with monitoring guidelines developed by physicians and pharmacists
Number of subjects: 9139
Study 16637791 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (control)
Number of subjects: 9139
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool for amiodarone monitoring
Number of subjects: 9139
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool for theophylline monitoring
Number of subjects: 9139
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool for carbamazepine monitoring
Number of subjects: 9139
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool for lithium monitoring
Number of subjects: 9139
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool for phenytoin monitoring
Number of subjects: 9139
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool for metformin monitoring
Number of subjects: 9139
Study 16637791 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests ordered
Number of subjects: 9139
Study 12786953 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 0
Study 12786953 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice
Number of subjects: 0
Study 11004356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 180
Study 11004356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8646249 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-heparin infusion
Number of subjects: 6
Study 8646249 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 1282182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (30 mg)
Number of subjects: 13
Study 1282182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 13
Study 1282182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6518296 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide scans every six months for the first three postoperative years and yearly thereafter.
Number of subjects: 2697
Study 6518296 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine bone scans
Number of subjects: 2697
Study 6518296 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly scans for asymptomatic patients with positive axillary nodes
Number of subjects: 2697
Study 29274034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL) 20 g/day
Number of subjects: 31
Study 29274034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 31
Study 29566746 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker
Number of subjects: 800
Study 29566746 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker plus incentive groups
Number of subjects: 800
Study 29566746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study 26931491 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPPY intervention (6 antenatal, 6 postnatal sessions), N=59
Number of subjects: 120
Study 26931491 — intervention group
Group type: COMPARATOR
Intervention: Usual care, N=61
Number of subjects: 120
Study 26931491 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPPY intervention
Number of subjects: 120
Study 24743062 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 285
Study 24743062 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 285
Study 24743062 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple somatic symptoms (measured by SCL‐SOM)
Number of subjects: 285
Study 24743062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickness absence (SA)
Number of subjects: 285
Study 24743062 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work (RTW)
Number of subjects: 285
Study 22727935 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+NHA
Number of subjects: 30
Study 22727935 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 30
Study 19437334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg per day for 7‐10 days
Number of subjects: 37
Study 19437334 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7‐10 days
Number of subjects: 37
Study 18158077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/d
Number of subjects: 268
Study 18158077 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 268
Study 16235010 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine
Number of subjects: 10
Study 16235010 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated girls with Rett syndrome)
Number of subjects: 10
Study 12098152 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic knee movements at speeds of 60 degrees/s, 180 degrees/s, and 300 degrees/s
Number of subjects: 20
Study 10409530 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 80 mg twice daily
Number of subjects: 41
Study 10409530 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg once daily
Number of subjects: 41
Study 7650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (published studies)
Number of subjects: 202
Study 7650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (individual patient data)
Number of subjects: 202
Study 7650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (unpublished trials)
Number of subjects: 202
Study 7650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (published studies, random treatment effect model)
Number of subjects: 202
Study 7650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (individual patient data, random treatment effect model)
Number of subjects: 202
Study 7650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (unpublished trials, random treatment effect model)
Number of subjects: 202
Study 1692988 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin (Gal) plus growth hormone‐releasing hormone (GHRH)
Number of subjects: 15
Study 1692988 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 15
Study 1692988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) plus Gal
Number of subjects: 15
Study 1692988 — intervention group
Group type: COMPARATOR
Intervention: Gal alone
Number of subjects: 15
Study 7417900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic spray (neomycin sulfate, polymyxin B sulfate, zinc bacitracin)
Number of subjects: 150
Study 7417900 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 150
Study 30711459 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-only strategy (n = 391)
Number of subjects: 782
Study 30711459 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer strategy (n = 391)
Number of subjects: 782
Study 30711459 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 782
Study 28198084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 196
Study 28198084 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 196
Study 22930789 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (target dose: 1.2 mg/kg per day)
Number of subjects: 125
Study 22930789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 23646472 — intervention group
Group type: EXPERIMENTAL
Intervention: Guizhi Fuling Decoction (GFD)
Number of subjects: 72
Study 23646472 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 72
Study 22195356 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (angiotensin II receptor blocker)
Number of subjects: 0
Study 22195356 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (control)
Number of subjects: 0
Study 19469697 — intervention group
Group type: EXPERIMENTAL
Intervention: brimonidine P 0.15%
Number of subjects: 1596
Study 19469697 — intervention group
Group type: EXPERIMENTAL
Intervention: brimonidine P 0.1%
Number of subjects: 1596
Study 17531918 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-ventricular assist device (LVAD) support
Number of subjects: 25
Study 17531918 — intervention group
Group type: COMPARATOR
Intervention: Inotropic drugs
Number of subjects: 25
Study 17531918 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 15238590 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 10027
Study 15238590 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10027
Study 11598594 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (30 to 45 minutes a day, 3 days per week, using 15 different resistance exercises)
Number of subjects: 67
Study 11598594 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 67
Study 11598594 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary, <2 hours of exercise per week)
Number of subjects: 67
Study 11598594 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study 9537703 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming
Number of subjects: 25
Study 9537703 — intervention group
Group type: COMPARATOR
Intervention: Passive heat preservation techniques
Number of subjects: 25
Study 7985599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol, Propranolol, Metoprolol, Atenolol, Hydrochlorothiazide
Number of subjects: 65
Study 7985599 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 65
Study 7985599 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade without intrinsic sympathomimetic activity and Hydrochlorothiazide
Number of subjects: 65
Study 2672774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (45 g, 9% of total daily energy) added to diet
Number of subjects: 0
Study 2672774 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (162 mg) added to diet
Number of subjects: 0
Study 2672774 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet without added sucrose or aspartame)
Number of subjects: 0
Study 338390 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 20
Study 338390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31630479 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg twice daily for seven days followed by 5 mg twice daily for six months
Number of subjects: 300
Study 31630479 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (200 IU/kg for one month followed by 150 IU/kg once daily)
Number of subjects: 300
Study 31196815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 17160
Study 31196815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study 28298543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program in Karimganj
Number of subjects: 2400
Study 25697717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mm injection depth of insulin lispro (0.25 U/kg)
Number of subjects: 0
Study 25697717 — intervention group
Group type: COMPARATOR
Intervention: 8-mm injection depth of insulin lispro (0.25 U/kg)
Number of subjects: 0
Study 23978642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose salbutamol (1μg)
Number of subjects: 12
Study 21356110 — intervention group
Group type: COMPARATOR
Intervention: MEDI-528 (0.3, 1, 3 mg/kg)
Number of subjects: 36
Study 21356110 — intervention group
Group type: COMPARATOR
Intervention: MEDI-528 (50 mg)
Number of subjects: 36
Study 19512882 — intervention group
Group type: EXPERIMENTAL
Intervention: Air LORT
Number of subjects: 360
Study 19512882 — intervention group
Group type: COMPARATOR
Intervention: Saline LORT
Number of subjects: 360
Study 19512882 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of initial fluid return
Number of subjects: 360
Study 17088125 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified allergen extracts containing 50% Dermatophagoides pteronyssinus and 50% Dermatophagoides farinae
Number of subjects: 64
Study 17088125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17088125 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified allergen extracts
Number of subjects: 64
Study 12970701 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter and confirmation slip
Number of subjects: 232
Study 12970701 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 232
Study 12970701 — intervention group
Group type: EXPERIMENTAL
Intervention: Social deprivation effect
Number of subjects: 232
Study 11249629 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic recombinant human antithrombin III (rhAT-III)
Number of subjects: 0
Study 11249629 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9138658 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran fiber (2.0 or 13.5 g/day)
Number of subjects: 100
Study 9138658 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (250 or 1500 mg/day)
Number of subjects: 100
Study 9138658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.0 g of wheat bran fiber plus 250 mg of calcium carbonate during 3-month run-in)
Number of subjects: 100
Study 8222940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic root canal instrumentation
Number of subjects: 432
Study 8222940 — intervention group
Group type: COMPARATOR
Intervention: Hand root canal instrumentation
Number of subjects: 432
Study 3899370 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg b.i.d.
Number of subjects: 31
Study 3899370 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 50 micrograms b.i.d.
Number of subjects: 31
Study 31420735 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful training with insufficient recovery (NFOR)
Number of subjects: 16
Study 31420735 — intervention group
Group type: COMPARATOR
Intervention: Normal training (CON)
Number of subjects: 16
Study 29154553 — intervention group
Group type: EXPERIMENTAL
Intervention: Female‐Specific Cognitive Behavioral Therapy (FS‐CBT)
Number of subjects: 99
Study 29154553 — intervention group
Group type: COMPARATOR
Intervention: Gender‐neutral Cognitive Behavioral Therapy (GN‐CBT)
Number of subjects: 99
Study 25886088 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream combined with salicylic acid 15%
Number of subjects: 86
Study 25886088 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 86
Study 23836239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use throughout the procedure (operative tourniquet group)
Number of subjects: 71
Study 23836239 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet use only during cementation (cementation tourniquet group)
Number of subjects: 71
Study 22350327 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational software for childbirth education for 6-8 weeks
Number of subjects: 150
Study 22350327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 150
Study 20546013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CHO
Number of subjects: 6
Study 20546013 — intervention group
Group type: EXPERIMENTAL
Intervention: High CHO
Number of subjects: 6
Study 20546013 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study 18794647 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg MDMA
Number of subjects: 15
Study 12568145 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 30
Study 12568145 — intervention group
Group type: COMPARATOR
Intervention: Superficial needle insertion (control)
Number of subjects: 30
Study 9735576 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized motivational brief intervention
Number of subjects: 348
Study 9735576 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 348
Study 9735576 — intervention group
Group type: COMPARATOR
Intervention: Natural history comparison group
Number of subjects: 348
Study 7981177 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly oxidized oil
Number of subjects: 0
Study 7981177 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-oxidized oil
Number of subjects: 0
Study 7981177 — intervention group
Group type: COMPARATOR
Intervention: Control corn oil
Number of subjects: 0
Study 7981177 — intervention group
Group type: COMPARATOR
Intervention: Control corn oil vs. Highly oxidized oil
Number of subjects: 0
Study 2741976 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, four times daily)
Number of subjects: 24
Study 2741976 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg, four times daily)
Number of subjects: 24
Study 2741976 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 24
Study 2741976 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg intravenously)
Number of subjects: 24
Study 31141968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration for 2 hours
Number of subjects: 8
Study 31141968 — intervention group
Group type: COMPARATOR
Intervention: Hypohydrated state
Number of subjects: 8
Study 31141968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration trial
Number of subjects: 8
Study 31141968 — intervention group
Group type: COMPARATOR
Intervention: Hypohydrated trial
Number of subjects: 8
Study 29390272 — intervention group
Group type: EXPERIMENTAL
Intervention: SQJZ herbal formula
Number of subjects: 240
Study 29390272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 26046622 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist footwear (MFW) and gait-retraining intervention (n = 13)
Number of subjects: 23
Study 26046622 — intervention group
Group type: COMPARATOR
Intervention: Minimalist footwear (MFW)
Number of subjects: 23